샘플 요청 목록

 카트 문의
시장보고서
상품코드
2037280

mRNA 암백신 시장(2026-2036년)

Global mRNA Cancer Vaccine Market Report 2026-2036
발행일: | 리서치사: 구분자 Visiongain | 페이지 정보: 영문 289 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



가격
Unprintable PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. PDF 내 텍스트 등의 복사 및 붙여넣기, 인쇄 불가능합니다.
US $ 5,959.50 금액 안내 화살표 ￦ 9,073,000
PDF (Team License - Up to 6 Users) help
PDF 보고서를 동일 사업장(소재지) 내 최대 6명까지 이용할 수 있는 라이선스입니다. 파일 내 텍스트 등의 복사 및 붙여넣기가 불가능합니다. 인쇄 가능하며 1인당 1회 가능합니다. 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 7,055.50 금액 안내 화살표 ￦ 10,742,000
PDF (Site License) help
PDF 보고서를 동일 사업장(소재지) 내 최대 6명까지 이용할 수 있는 라이선스입니다. 파일 내 텍스트 등의 복사 및 붙여넣기가 불가능합니다. 인쇄 가능하며 1인당 1회 가능합니다. 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,288.50 금액 안내 화살표 ￦ 12,620,000
PDF (Enterprise License - Includes Free Datasets) help
PDF 보고서를 동일 사업장(소재지)의 모든 분이 이용할 수 있는 라이선스입니다. 파일 내 텍스트 등의 복사 및 붙여넣기가 불가능합니다. 인쇄 가능하며 1인당 1회 가능합니다. 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 10,473.65 금액 안내 화살표 ￦ 15,947,000
※ 부가세 별도
한글목차
영문목차
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

전 세계 mRNA 암 백신 시장 규모는 2036년까지 연평균 27.1%의 성장률을 보일 것으로 예상됩니다.

세계의 mRNA 암 백신 시장에 대해 조사 분석했으며, 시장 규모, 수요 촉진요인, 경쟁 환경, 주요 부문별 매출 예측 등의 정보를 전해드립니다.

세계의 mRNA 암 백신 시장은 2026년 12억 달러를 넘어설 것으로 예상되며, 정밀 종양의 역할 확대, 시퀀싱 기술의 발전, 임상 후보물질 파이프라인의 확대에 힘입어 2036년까지 견고한 성장이 예상됩니다.

이러한 성장 궤적은 개별 게놈 프로파일에 기반한 맞춤형 종양 표적 면역요법을 생성하는 mRNA 플랫폼의 능력과 신항원 발굴 및 첨단 전달 시스템의 지속적인 혁신에 의해 지원되고 있습니다.

게놈 시퀀싱과 신항원 예측 알고리즘의 발전으로 차세대 맞춤형 mRNA 암 백신 개발이 가속화되고 있습니다. 이러한 플랫폼은 종양 특이적 돌연변이를 정밀하게 표적화하여 치료 효과를 높이고, 정밀 종양 치료 경로에 원활하게 통합될 수 있도록 돕습니다.

자가 증폭 mRNA 구조체 및 개선된 지질 나노입자 전달 시스템을 포함한 플랫폼 수준의 혁신은 확장성을 향상시키고 개발 기간을 단축하여 mRNA 백신이 차세대 종양학 분야의 주요 치료제로서의 입지를 확고히 하고 있습니다.

상업적 영향

  • 비용 및 가격 책정 압력 : 투입 및 제조 비용의 증가로 인해 치료의 경제적 부담이 가중 될 수 있습니다.
  • 공급망의 변화: 지역 제조 및 조달의 탄력성에 대한 관심이 높아지고 있습니다.
  • 규제 영향: 승인 절차 및 규정 준수 의무가 개발 일정에 영향을 미치고 있습니다.
  • 경쟁적 포지셔닝: 확장 가능한 플랫폼과 탄탄한 파트너십 네트워크를 보유한 기업이 유리한 위치에 있습니다.

이 보고서는 경쟁적 포지셔닝이 어떻게 변화하고 있는지, 가치가 어디에서 창출되고 있는지, 그리고 예측 기간 중 전략이 어떻게 진화할 것으로 예상되는지 살펴봅니다.

주요 질문에 대한 답변

  • mRNA 암 백신 시장은 어떻게 진화하고 있는가?
  • 시장 성장을 촉진하는 요인과 억제하는 요인은 무엇인가?
  • 가장 큰 매출을 창출하는 부문과 지역은 어디인가?
  • 무역, 정책, 공급망 동향이 시장에 어떤 영향을 미치는가?
  • 주요 기업은 어디에 있으며, 그 전망은 어떠한가?

목차

제1장 리포트 개요

제2장 개요

제3장 시장 개요

  • 주요 조사 결과
  • 시장 역학
  • 영향 분석
    • 시장 성장 촉진요인
    • 시장 성장 억제요인
    • 시장 기회
  • 미국의 관세 : 세계의 mRNA 암 백신 시장에 대한 영향은?
  • Porter's Five Forces 분석
  • PEST 분석

제4장 mRNA 암 백신 시장 분석 : 적응증별

  • 주요 조사 결과
  • 시장의 매력 지수
  • 시장 규모 추정·예측
  • 고TMB 고형 종양
  • 소화기암
  • 부인과암
  • 유방암
  • 기타 고형 종양
    • 시장 규모 : 지역별
    • 시장 점유율 : 지역별

제5장 mRNA 암 백신 시장 분석 : 플랫폼 유형별

  • 주요 조사 결과
  • 시장의 매력 지수
  • 시장 규모 추정·예측
  • 개별화 백신
  • OTC 백신
  • 반개별화 백신
    • 시장 규모 : 지역별
    • 시장 점유율 : 지역별

제6장 mRNA 암 백신 시장 분석 : 치료 어프로치별

  • 주요 조사 결과
  • 시장의 매력 지수
  • 시장 규모 추정·예측
  • 단독요법
  • 병용요법
    • 시장 규모 : 지역별
    • 시장 점유율 : 지역별

제7장 mRNA 암 백신 시장 분석 : 스테이지별

  • 주요 조사 결과
  • 시장의 매력 지수
  • 시장 규모 추정·예측
  • 제I상
  • 제II상
  • 제III상
  • 제IV상
    • 시장 규모 : 지역별
    • 시장 점유율 : 지역별

제8장 mRNA 암 백신 시장 분석 : 최종사용자별

  • 주요 조사 결과
  • 시장의 매력 지수
  • 시장 규모 추정·예측
  • 바이오의약품·바이오테크놀러지 기업
  • 의약품 개발·제조 수탁 기관(CDMO)
  • 연구기관 및 학술 센터
  • 병원 및 전문 암센터
    • 시장 규모 : 지역별
    • 시장 점유율 : 지역별

제9장 mRNA 암 백신 시장 분석 : 지역별

  • 주요 조사 결과
  • 시장 규모 추정·예측

제10장 북미의 mRNA 암 백신 시장 분석

제11장 유럽의 mRNA 암 백신 시장 분석

제12장 아시아태평양의 mRNA 암 백신 시장 분석

제13장 라틴아메리카의 mRNA 암 백신 시장 분석

제14장 중동 및 아프리카의 mRNA 암 백신 시장 분석

제15장 기업 개요

  • 경쟁 환경
  • 전략적 전망
  • Moderna, Inc.
  • BioNTech SE
  • Arcturus Therapeutics, Inc.
  • etherna
  • ETHRIS
  • ImmuneSensor Therapeutics
  • Chimeron Bio
  • Replimune Group Inc.
  • ST Pharm
  • Sana Biotechnology
  • Cartesian Therapeutics Inc.
  • Strand Therapeutics
  • Acuitas

제16장 결론·제안

  • Visiongain으로부터의 결론
  • 참여 기업에 대한 권장사항
KSA

The global mRNA Cancer Vaccine market is projected to grow at a CAGR of 27.1% by 2036.

Visiongain has released its latest report, mRNA Cancer Vaccine Market Report 2026-2036, delivering a thorough examination of the global mRNA cancer vaccine market, covering market sizing, demand drivers, competitive dynamics, and revenue projections across core segments.

The global mRNA cancer vaccine market is expected to surpass US$1,200.0 million in 2026, with robust growth projected through to 2036, driven by the expanding role of precision oncology, breakthroughs in sequencing technologies, and a growing pipeline of clinical candidates.

This trajectory is supported by the ability of mRNA platforms to generate personalised, tumour-targeted immunotherapies based on individual genomic profiles, alongside continued innovation in neoantigen identification and advanced delivery systems.

Progress in genomic sequencing and neoantigen prediction algorithms is accelerating the development of next-generation personalised mRNA cancer vaccines. These platforms enable precise targeting of tumour-specific mutations, enhancing therapeutic effectiveness and supporting seamless integration into precision oncology treatment pathways.

Platform-level innovations - including self-amplifying mRNA constructs and improved lipid nanoparticle delivery systems - are enhancing scalability and compressing development timelines, cementing mRNA vaccines as a leading modality in next-generation oncology.

Trade Flows, Policy Shifts & Supply Chain Pressures

The mRNA cancer vaccine market is increasingly shaped by global trade conditions, evolving regulatory frameworks, and supply chain dependencies.

Production depends on specialised inputs - including lipid nanoparticles, nucleotides, and enzymes - sourced from global supply networks. Tariffs and trade restrictions have the potential to increase input costs and disrupt supply chains, with downstream effects on development timelines and commercial pricing.

Regulatory requirements and international collaboration also play a pivotal role in clinical development and route-to-market strategy, shaping access timelines and competitive positioning across key geographies.

Commercial Implications

  • Cost and pricing pressure: Rising input and manufacturing costs may weigh on therapy affordability
  • Supply chain shifts: Growing focus on regional manufacturing and sourcing resilience
  • Regulatory influence: Approval pathways and compliance obligations are shaping development timelines
  • Competitive positioning: Companies with scalable platforms and strong partnership networks are better placed

Company Intelligence

The mRNA cancer vaccine market features a blend of established biotechnology leaders and emerging innovators competing on platform capability, clinical progress, and the strength of their strategic alliances.

Key players including BioNTech, Moderna, Arcturus Therapeutics, and Sana Biotechnology are advancing their positions through clinical development, platform innovation, and targeted collaboration activity.

Competitive differentiation is increasingly driven by:

  • Technology and platform differentiation
  • Clinical pipeline strength
  • Manufacturing capability and scalability
  • Strategic partnerships and collaborations

This report examines how competitive positioning is shifting, pinpointing where value is being created and how strategies are expected to evolve across the forecast period.

Key Questions Answered

  • How is the mRNA cancer vaccine market evolving?
  • What is driving and restraining market growth?
  • Which segments and regions will generate the most revenue?
  • How will trade, policy, and supply chain dynamics impact the market?
  • Who are the leading companies and what are their prospects?

Report Scope and Data Coverage

  • Global mRNA cancer vaccine market analysis
  • Revenue forecasts to 2036
  • Segment-level modelling across vaccine type, therapeutic approach, phase, indication, and end-user
  • Regional and national market forecasts
  • Competitive intelligence on leading companies

Covers both quantitative forecasting and qualitative strategic analysis across technology, competition, policy, and supply chain dimensions.

Segmentation Framework

By Vaccine Type

  • Personalised
  • Semi-Personalised
  • Off-the-Shelf

By Therapeutic Approach

  • Monotherapy
  • Combination Therapy

By Phase

  • Phase I
  • Phase II
  • Phase III
  • Phase IV

By Indication

  • High TMB Solid Tumors
  • GI Cancers
  • Gynecological Cancers
  • Breast Cancer
  • Other Solid Tumours

By End-user

  • Biopharma & Biotechnology Companies
  • Contract Development & Manufacturing Organisations (CDMOs)
  • Research Institutes & Academic Centres
  • Hospitals & Specialised Cancer Centres

Geographic Coverage

North America

  • U.S.
  • Canada

Europe

  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe

Asia Pacific

  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific

Latin America

  • Brazil
  • Mexico
  • Rest of Latin America

Middle East & Africa

  • GCC
  • South Africa
  • Rest of MEA

Company Intelligence Coverage

This report includes detailed profiles of leading companies such as:

  • Acuitas
  • Arcturus Therapeutics
  • BioNTech
  • Cartesian Therapeutics Inc
  • Chimeron Bio
  • eTheRNA
  • Ethris GmbH
  • ImmuneSensor Therapeutics
  • Moderna
  • Orna Therapeutics
  • Replimune Group
  • Sana Biotechnology
  • ST Pharm
  • Strand Therapeutics

Each profile includes:

  • Business overview
  • Financial and market positioning
  • Product and technology capabilities
  • Strategic outlook

Bespoke Intelligence & Customisation

Visiongain also provides tailored intelligence and advisory support aligned to specific client requirements.

This includes:

  • Custom market segmentation and forecasts
  • Competitive benchmarking and strategy analysis
  • Policy and regulatory impact assessment
  • Supply chain and sourcing intelligence
  • Scenario modelling including tariffs and geopolitical risk

Why This Market Intelligence Matters

  • The mRNA cancer vaccine market is moving quickly, propelled by precision medicine, platform innovation, and shifting global supply dynamics.
  • Organisations that understand these trends will be better placed to capture growth opportunities, manage risk, and strengthen their competitive positioning.

Table of Contents

1 Report Overview

  • 1.1 Objectives of the Study
  • 1.2 Introduction to mRNA Cancer Vaccine Market
  • 1.3 What This Report Delivers
  • 1.4 Why You Should Read This Report
  • 1.5 Key Questions Answered by This Analytical Report
  • 1.6 Who is This Report for?
  • 1.7 Methodology
    • 1.7.1 Market Definitions
    • 1.7.2 Market Evaluation & Forecasting Methodology
    • 1.7.3 Data Validation
      • 1.7.3.1 Primary Research
      • 1.7.3.2 Secondary Research
  • 1.8 Frequently Asked Questions (FAQs)
  • 1.9 Associated Visiongain Reports
  • 1.10 About Visiongain

2 Executive Summary

3 Market Overview

  • 3.1 Key Findings
  • 3.2 Market Dynamics
  • 3.3 Impact Analysis
    • 3.3.1 Market Driving Factors
      • 3.3.1.1 Late-Stage Clinical Validation Strengthening Commercial Confidence
      • 3.3.1.2 Dedicated Oncology Manufacturing and Automation Scale-Up
      • 3.3.1.3 Strategic Big Pharma Alliances and Capital Deployment
    • 3.3.2 Market Restraining Factors
      • 3.3.2.1 Operational Complexity of Individualized Vaccine Workflows
      • 3.3.2.2 Regulatory and Reimbursement Uncertainty for Novel Oncology Platforms
      • 3.3.2.3 Competitive Landscape of Established and Emerging Immunotherapies
    • 3.3.3 Market Opportunities
      • 3.3.3.1 Expansion into Early-Stage and Adjuvant Cancer Settings
      • 3.3.3.2 Platform Replicability Across Multiple Tumor Types
      • 3.3.3.3 Strengthening mRNA Oncology Ecosystem and Infrastructure Investment
  • 3.4 U.S. Tariffs: What's the Impact on Global mRNA Cancer Vaccine Market?
    • 3.4.1 Overview
    • 3.4.2 V-Shaped Recovery Scenario
      • 3.4.2.1 Why V-Shaped Recovery?
      • 3.4.2.2 Impact from Tariffs
      • 3.4.2.3 Market Dynamics and Demand Recovery
      • 3.4.2.4 Policy and Funding Support
    • 3.4.3 U-Shaped Recovery Scenario
      • 3.4.3.1 Why U-Shaped Recovery?
      • 3.4.3.2 Impact from Tariffs
      • 3.4.3.3 Timeframe for Recovery
      • 3.4.3.4 Policy and Funding Support
    • 3.4.4 L Shaped Recovery Scenario
      • 3.4.4.1 Why L-Shaped Recovery?
      • 3.4.4.2 Impact from Tariffs
      • 3.4.4.3 Market Dynamics and Demand Recovery
      • 3.4.4.4 Policy and Funding Support
    • 3.4.5 What Strategic Considerations Should Clients Factor into Their Near-term (2026-2031) and Long-term (2026-2036) Planning?
    • 3.4.6 Impact of U.S. and China Trade War on mRNA Cancer Vaccine Market
    • 3.4.7 How Might the Most Impacted Countries Experience Positive and Negative Effects Resulting from These Policy Changes?
    • 3.4.8 Global Market Tariff Sensitivity and Margin Pressure Analysis
  • 3.5 Porter's Five Forces Analysis
    • 3.5.1 Bargaining Power of Suppliers
    • 3.5.2 Bargaining Power of Buyers
    • 3.5.3 Competitive Rivalry
    • 3.5.4 Threat of Substitutes
    • 3.5.5 Threat of New Entrants
  • 3.6 PEST Analysis

4 mRNA Cancer Vaccine Market Analysis by Indication

  • 4.1 Key Findings
  • 4.2 Indication Segment: Market Attractiveness Index
  • 4.3 mRNA Cancer Vaccine Market Size Estimation and Forecast by Indication
  • 4.4 High TMB Solid Tumors
    • 4.4.1 Market Size by Region, 2026-2036 (US$ Million)
    • 4.4.2 Market Share by Region, 2026 & 2036 (%)
  • 4.5 GI Cancers
    • 4.5.1 Market Size by Region, 2026-2036 (US$ Million)
    • 4.5.2 Market Share by Region, 2026 & 2036 (%)
  • 4.6 Gynecological Cancers
    • 4.6.1 Market Size by Region, 2026-2036 (US$ Million)
    • 4.6.2 Market Share by Region, 2026 & 2036 (%)
  • 4.7 Breast Cancers
    • 4.7.1 Market Size by Region, 2026-2036 (US$ Million)
    • 4.7.2 Market Share by Region, 2026 & 2036 (%)
  • 4.8 Other Solid Tumors
    • 4.8.1 Market Size by Region, 2026-2036 (US$ Million)
    • 4.8.2 Market Share by Region, 2026 & 2036 (%)

5 mRNA Cancer Vaccine Market Analysis by Platform Type

  • 5.1 Key Findings
  • 5.2 Platform Type Segment: Market Attractiveness Index
  • 5.3 mRNA Cancer Vaccine Market Size Estimation and Forecast by Platform Type
  • 5.4 Personalized
    • 5.4.1 Market Size by Region, 2026-2036 (US$ Million)
    • 5.4.2 Market Share by Region, 2026 & 2036 (%)
  • 5.5 Off-the-Shelf
    • 5.5.1 Market Size by Region, 2026-2036 (US$ Million)
    • 5.5.2 Market Share by Region, 2026 & 2036 (%)
  • 5.6 Semi-Personalized
    • 5.6.1 Market Size by Region, 2026-2036 (US$ Million)
    • 5.6.2 Market Share by Region, 2026 & 2036 (%)

6 mRNA Cancer Vaccine Market Analysis by Therapeutic Approach

  • 6.1 Key Findings
  • 6.2 Therapeutic Approach Segment: Market Attractiveness Index
  • 6.3 mRNA Cancer Vaccine Market Size Estimation and Forecast by Therapeutic Approach
  • 6.4 Monotherapy
    • 6.4.1 Market Size by Region, 2026-2036 (US$ Million)
    • 6.4.2 Market Share by Region, 2026 & 2036 (%)
  • 6.5 Combination Therapy
    • 6.5.1 Market Size by Region, 2026-2036 (US$ Million)
    • 6.5.2 Market Share by Region, 2026 & 2036 (%)

7 mRNA Cancer Vaccine Market Analysis by Phases

  • 7.1 Key Findings
  • 7.2 Phases Segment: Market Attractiveness Index
  • 7.3 mRNA Cancer Vaccine Market Size Estimation and Forecast by Phases
  • 7.4 Phase I
    • 7.4.1 Market Size by Region, 2026-2036 (US$ Million)
    • 7.4.2 Market Share by Region, 2026 & 2036 (%)
  • 7.5 Phase II
    • 7.5.1 Market Size by Region, 2026-2036 (US$ Million)
    • 7.5.2 Market Share by Region, 2026 & 2036 (%)
  • 7.6 Phase III
    • 7.6.1 Market Size by Region, 2026-2036 (US$ Million)
    • 7.6.2 Market Share by Region, 2026 & 2036 (%)
  • 7.7 Phase IV
    • 7.7.1 Market Size by Region, 2026-2036 (US$ Million)
    • 7.7.2 Market Share by Region, 2029 & 2036 (%)

8 mRNA Cancer Vaccine Market Analysis by End-users

  • 8.1 Key Findings
  • 8.2 End Users Segment: Market Attractiveness Index
  • 8.3 mRNA Cancer Vaccine Market Size Estimation and Forecast by End Users
  • 8.4 Biopharma & Biotechnology Companies
    • 8.4.1 Market Size by Region, 2026-2036 (US$ Million)
    • 8.4.2 Market Share by Region, 2026 & 2036 (%)
  • 8.5 Contract Development & Manufacturing Organizations (CDMOs)
    • 8.5.1 Market Size by Region, 2026-2036 (US$ Million)
    • 8.5.2 Market Share by Region, 2026 & 2036 (%)
  • 8.6 Research Institutes & Academic Centers
    • 8.6.1 Market Size by Region, 2026-2036 (US$ Million)
    • 8.6.2 Market Share by Region, 2026 & 2036 (%)
  • 8.7 Hospitals & Specialized Cancer Centers
    • 8.7.1 Market Size by Region, 2026-2036 (US$ Million)
    • 8.7.2 Market Share by Region, 2026 & 2036 (%)

9 mRNA Cancer Vaccine Market Analysis by Region

  • 9.1 Key Findings
  • 9.2 Regional Market Size Estimation and Forecast

10 North America mRNA Cancer Vaccine Market Analysis

  • 10.1 Key Findings
  • 10.2 North America mRNA Cancer Vaccine Market Attractiveness Index
  • 10.3 North America mRNA Cancer Vaccine Market by Country, 2026, 2031 & 2036 (US$ Million)
  • 10.4 North America mRNA Cancer Vaccine Market Size Estimation and Forecast by Country
  • 10.5 North America mRNA Cancer Vaccine Market Size Estimation and Forecast by Indication
  • 10.6 North America mRNA Cancer Vaccine Market Size Estimation and Forecast by Platform Type
  • 10.7 North America mRNA Cancer Vaccine Market Size Estimation and Forecast by Therapeutic Approach
  • 10.8 North America mRNA Cancer Vaccine Market Size Estimation and Forecast by Phases
  • 10.9 North America mRNA Cancer Vaccine Market Size Estimation and Forecast by End Users
  • 10.10 U.S. mRNA Cancer Vaccine Market Analysis
  • 10.11 Canada mRNA Cancer Vaccine Market Analysis

11 Europe mRNA Cancer Vaccine Market Analysis

  • 11.1 Key Findings
  • 11.2 Europe mRNA Cancer Vaccine Market Attractiveness Index
  • 11.3 Europe mRNA Cancer Vaccine Market by Country, 2026, 2031 & 2036 (US$ Million)
  • 11.4 Europe mRNA Cancer Vaccine Market Size Estimation and Forecast by Country
  • 11.5 Europe mRNA Cancer Vaccine Market Size Estimation and Forecast by Indication
  • 11.6 Europe mRNA Cancer Vaccine Market Size Estimation and Forecast by Platform Type
  • 11.7 Europe mRNA Cancer Vaccine Market Size Estimation and Forecast by Therapeutic Approach
  • 11.8 Europe mRNA Cancer Vaccine Market Size Estimation and Forecast by Phases
  • 11.9 Europe mRNA Cancer Vaccine Market Size Estimation and Forecast by End Users
  • 11.10 Germany mRNA Cancer Vaccine Market Analysis
  • 11.11 France mRNA Cancer Vaccine Market Analysis
  • 11.12 UK mRNA Cancer Vaccine Market Analysis
  • 11.13 Italy mRNA Cancer Vaccine Market Analysis
  • 11.14 Spain mRNA Cancer Vaccine Market Analysis
  • 11.15 Rest of Europe mRNA Cancer Vaccine Market Analysis

12 Asia Pacific mRNA Cancer Vaccine Market Analysis

  • 12.1 Key Findings
  • 12.2 Asia Pacific mRNA Cancer Vaccine Market Attractiveness Index
  • 12.3 Asia Pacific mRNA Cancer Vaccine Market by Country, 2026, 2031 & 2036 (US$ Million)
  • 12.4 Asia Pacific mRNA Cancer Vaccine Market Size Estimation and Forecast by Country
  • 12.5 Asia Pacific mRNA Cancer Vaccine Market Size Estimation and Forecast by Indication
  • 12.6 Asia Pacific mRNA Cancer Vaccine Market Size Estimation and Forecast by Platform Type
  • 12.7 Asia Pacific mRNA Cancer Vaccine Market Size Estimation and Forecast by Therapeutic Approach
  • 12.8 Asia Pacific mRNA Cancer Vaccine Market Size Estimation and Forecast by Phases
  • 12.9 Asia Pacific mRNA Cancer Vaccine Market Size Estimation and Forecast by End Users
  • 12.10 Japan mRNA Cancer Vaccine Market Analysis
  • 12.11 China mRNA Cancer Vaccine Market Analysis
  • 12.12 India mRNA Cancer Vaccine Market Analysis
  • 12.13 Australia mRNA Cancer Vaccine Market Analysis
  • 12.14 South Korea mRNA Cancer Vaccine Market Analysis
  • 12.15 Rest of Asia Pacific mRNA Cancer Vaccine Market Analysis

13 Latin America mRNA Cancer Vaccine Market Analysis

  • 13.1 Key Findings
  • 13.2 Latin America mRNA Cancer Vaccine Market Attractiveness Index
  • 13.3 Latin America mRNA Cancer Vaccine Market by Country, 2026, 2031 & 2036 (US$ Million)
  • 13.4 Latin America mRNA Cancer Vaccine Market Size Estimation and Forecast by Country
  • 13.5 Latin America mRNA Cancer Vaccine Market Size Estimation and Forecast by Indication
  • 13.6 Latin America mRNA Cancer Vaccine Market Size Estimation and Forecast by Platform Type
  • 13.7 Latin America mRNA Cancer Vaccine Market Size Estimation and Forecast by Therapeutic Approach
  • 13.8 Latin America mRNA Cancer Vaccine Market Size Estimation and Forecast by Phases
  • 13.9 Latin America mRNA Cancer Vaccine Market Size Estimation and Forecast by End Users
  • 13.10 Brazil mRNA Cancer Vaccine Market Analysis
  • 13.11 Mexico mRNA Cancer Vaccine Market Analysis
  • 13.12 Rest of Latin America mRNA Cancer Vaccine Market Analysis

14 MEA mRNA Cancer Vaccine Market Analysis

  • 14.1 Key Findings
  • 14.2 MEA mRNA Cancer Vaccine Market Attractiveness Index
  • 14.3 MEA mRNA Cancer Vaccine Market by Country, 2026, 2031 & 2036 (US$ Million)
  • 14.4 MEA mRNA Cancer Vaccine Market Size Estimation and Forecast by Country
  • 14.5 MEA mRNA Cancer Vaccine Market Size Estimation and Forecast by Indication
  • 14.6 MEA mRNA Cancer Vaccine Market Size Estimation and Forecast by Platform Type
  • 14.7 MEA mRNA Cancer Vaccine Market Size Estimation and Forecast by Therapeutic Approach
  • 14.8 MEA mRNA Cancer Vaccine Market Size Estimation and Forecast by Phases
  • 14.9 MEA mRNA Cancer Vaccine Market Size Estimation and Forecast by End Users
  • 14.10 GCC mRNA Cancer Vaccine Market Analysis
  • 14.11 South Africa mRNA Cancer Vaccine Market Analysis
  • 14.12 Rest of MEA mRNA Cancer Vaccine Market Analysis

15 Company Profiles

  • 15.1 Competitive Landscape, 2026
  • 15.2 Strategic Outlook
  • 15.3 Moderna, Inc.
    • 15.3.1 Company Snapshot
    • 15.3.2 Company Overview
    • 15.3.3 Financial Analysis
      • 15.3.3.1 Net Revenue, 2021-2025
      • 15.3.3.2 R&D, 2021-2025
      • 15.3.3.3 Regional Market Shares, 2025
      • 15.3.3.4 Business Segment Market Shares, 2025
    • 15.3.4 Product Benchmarking
    • 15.3.5 SWOT Analysis
    • 15.3.6 Strategic Outlook
  • 15.4 BioNTech SE
    • 15.4.1 Company Snapshot
    • 15.4.2 Company Overview
    • 15.4.3 Financial Analysis
      • 15.4.3.1 Net Revenue, 2021-2025
      • 15.4.3.2 R&D, 2021-2025
    • 15.4.4 Product Benchmarking
    • 15.4.5 SWOT Analysis
    • 15.4.6 Strategic Outlook
  • 15.5 Arcturus Therapeutics, Inc.
    • 15.5.1 Company Snapshot
    • 15.5.2 Company Overview
    • 15.5.3 Financial Analysis
      • 15.5.3.1 Net Revenue, 2021-2025
      • 15.5.3.2 R&D, 2021-2025
      • 15.5.3.3 Business Segment Market Shares, 2025
    • 15.5.4 Product Benchmarking
    • 15.5.5 SWOT Analysis
    • 15.5.6 Strategic Outlook
  • 15.6 etherna
    • 15.6.1 Company Snapshot
    • 15.6.2 Company Overview
    • 15.6.3 Product Benchmarking
    • 15.6.4 SWOT Analysis
    • 15.6.5 Strategic Outlook
  • 15.7 ETHRIS
    • 15.7.1 Company Snapshot
    • 15.7.2 Company Overview
    • 15.7.3 Product Benchmarking
    • 15.7.4 Strategic Outlook
  • 15.8 ImmuneSensor Therapeutics
    • 15.8.1 Company Snapshot
    • 15.8.2 Company Overview
    • 15.8.3 Product Benchmarking
    • 15.8.4 Strategic Outlook
  • 15.9 Chimeron Bio
    • 15.9.1 Company Snapshot
    • 15.9.2 Company Overview
    • 15.9.3 Product Benchmarking
    • 15.9.4 Strategic Outlook
  • 15.10 Replimune Group Inc.
    • 15.10.1 Company Snapshot
    • 15.10.2 Company Overview
    • 15.10.3 Product Benchmarking
  • 15.11 ST Pharm
    • 15.11.1 Company Snapshot
    • 15.11.2 Company Overview
    • 15.11.3 Product Benchmarking
    • 15.11.4 Strategic Outlook
  • 15.12 Sana Biotechnology
    • 15.12.1 Company Snapshot
    • 15.12.2 Company Overview
    • 15.12.3 Product Benchmarking
  • 15.13 Cartesian Therapeutics Inc.
    • 15.13.1 Company Snapshot
    • 15.13.2 Company Overview
    • 15.13.3 Financial Analysis
      • 15.13.3.1 Net Revenue, 2021-2025
      • 15.13.3.2 R&D, 2021-2025
    • 15.13.4 Product Benchmarking
  • 15.14 Strand Therapeutics
    • 15.14.1 Company Snapshot
    • 15.14.2 Company Overview
    • 15.14.3 Product Benchmarking
    • 15.14.4 Strategic Outlook
  • 15.15 Acuitas
    • 15.15.1 Company Snapshot
    • 15.15.2 Company Overview
    • 15.15.3 Product Benchmarking
    • 15.15.4 Strategic Outlook

16 Conclusion and Recommendations

  • 16.1 Concluding Remarks from Visiongain
  • 16.2 Recommendations for Market Players
×

원하시는 정보를 찾아 드릴까요?

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제
문의
원하시는 정보를
찾아 드릴까요?
문의주시면 필요한 정보를
신속하게 찾아드릴게요.
02-2025-2992
kr-info@giikorea.co.kr
문의하기